Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas

International Journal of Cancer

Volumn 131, Issue 8, 2012, Pages 1854-1862

  Burrell, Jake S ^a   Walker Samuel, Simon ^a,b   Baker, Lauren C J ^a   Boult, Jessica K R ^a   Jamin, Yann ^a   Ryan, Anderson J ^c,d   Waterton, John C ^c   Halliday, Jane ^c   Robinson, Simon P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cediranib; CUSPIO; MRI; remodeling; vasculature

Indexed keywords

CARBOGEN; CEDIRANIB; HOE 33342; PIMONIDAZOLE; SMOOTH MUSCLE ACTIN; TUMOR MARKER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL FUNCTION; BLOOD VESSEL PARAMETERS; BLOOD VOLUME; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG UPTAKE; GLIOMA; HEMODYNAMICS; HISTOPATHOLOGY; HYPOXIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; PERFUSION; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; TUMOR HYPOXIA; TUMOR PLASMA PERFUSION; TUMOR VASCULAR MATURATION; TUMOR VASCULAR NECROSIS; TUMOR VASCULARIZATION; VASCULAR NECROSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZIMIDAZOLES; CONTRAST MEDIA; DEXTRANS; FLUORESCENT DYES; GLIOMA; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; NITROIMIDAZOLES; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; RATS; RATS, NUDE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84865338089     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27460     Document Type: Article

References (42)

1. Folkman J,. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-86. (Pubitemid 46505878)
2. Fidler IJ, Ellis LM,. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-8. (Pubitemid 24324908)
3. Ferrara N, Davis-Smyth T,. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25. (Pubitemid 27076453)
4. Ferrara N, Gerber HP, LeCouter J,. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76. (Pubitemid 36749215)
5. Bates DO, Lodwick D, Williams B,. Vascular endothelial growth factor and microvascular permeability. Microcirculation 1999; 6: 83-96. (Pubitemid 129671107)
6. Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H, Kristjansen PE,. Tumor angiogenesisâ€"a new therapeutic target in gliomas. Acta Neurol Scand 1998; 97: 52-62. (Pubitemid 28057388)
7. Ferrara N, Hillan KJ, Gerber HP, Novotny W,. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400. (Pubitemid 38618122)
8. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-400. (Pubitemid 40775678)
9. Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Waterton JC,. Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126. Int J Radiat Oncol Biol Phys 2007; 69: 872-9. (Pubitemid 47418423)
10. Bradley DP, Tessier JL, Checkley D, Kuribayashi H, Waterton JC, Kendrew J, Wedge SR,. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR Biomed 2008; 21: 42-52. (Pubitemid 351227752)
11. Medinger M, Esser N, Zirrgiebel U, Ryan A, Jurgensmeier JM, Drevs J,. Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma. Anticancer Res 2009; 29: 5065-76.
12. Michaelis LC, Ratain MJ,. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006; 6: 409-14.
13. Padhani AR,. MRI for assessing antivascular cancer treatments. Br J Radiol 2003; 76: S60-80. (Pubitemid 39530317)
14. Padhani AR, Khan AA,. Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Target Oncol 2010; 5: 39-52.
15. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-64. (Pubitemid 46606209)
16. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005; 92: 1599-610. (Pubitemid 40756468)
17. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004; 10: 3650-7. (Pubitemid 38697598)
18. Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, Buchert M, Unger C, Blum H, Hennig J, Milenkova TP, Tessier J, Krebs AD, et al. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res 2009; 1: 5.
19. Wang H, Marchal G, Ni Y,. Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World J Radiol 2011; 3: 1-16.
20. Zweifel M, Padhani AR,. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging 2011; 37 (Suppl 1): S164-82.
21. Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Ryan AJ, Waterton JC, Halliday J, Robinson SP,. Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging. Magn Reson Med 2011; 66: 227-34.
22. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 1555-77.
23. Walker-Samuel S, Orton M, McPhail LD, Boult JK, Box G, Eccles SA, Robinson SP,. Bayesian estimation of changes in transverse relaxation rates. Magn Reson Med 2010; 64: 914-21.
24. Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, Waterton JC,. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003; 88: 1592-7. (Pubitemid 36713788)
25. Lyng H, Sundfor K, Rofstad EK,. Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia. Radiother Oncol 1997; 44: 163-9. (Pubitemid 27345204)
26. Bradley DP, Tessier JJ, Lacey T, Scott M, Jurgensmeier JM, Odedra R, Mills J, Kilburn L, Wedge SR,. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magn Reson Imaging 2009; 27: 377-84.
27. Neeman M, Dafni H, Bukhari O, Braun RD, Dewhirst MW,. In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy. Magn Reson Med 2001; 45: 887-98. (Pubitemid 32402032)
28. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J,. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
29. Carmeliet P, Conway EM,. Growing better blood vessels. Nat Biotechnol 2001; 19: 1019-20.
30. Dewhirst MW, Cao Y, Moeller B,. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8: 425-37. (Pubitemid 351744964)
31. Robinson SP, Rodrigues LM, Ojugo AS, McSheehy PM, Howe FA, Griffiths JR,. The response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging. Br J Cancer 1997; 75: 1000-6. (Pubitemid 27122618)
32. Karczmar GS, River JN, Li J, Vijayakumar S, Goldman Z, Lewis MZ,. Effects of hyperoxia on T2* and resonance frequency weighted magnetic resonance images of rodent tumours. NMR Biomed 1994; 7: 3-11. (Pubitemid 2085018)
33. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR,. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001; 14: 497-506. (Pubitemid 33150238)
34. Baudelet C, Gallez B,. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magn Reson Med 2002; 48: 980-6. (Pubitemid 35398527)
35. JuanYin J, Tracy K, Zhang L, Munasinghe J, Shapiro E, Koretsky A, Kelly K,. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis 2009; 26: 403-14.
36. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009; 69: 5296-300.
37. Dietrich J, Wang D, Batchelor TT,. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs 2009; 18: 1549-57.
38. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95. (Pubitemid 46075199)
39. Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti C, Subramanian S, Devasahayam N, Munasinghe JP, Mitchell JB, Krishna MC,. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 2011; 71: 6350-9.
40. Tai JH, Tessier J, Ryan AJ, Hoffman L, Chen X, Lee TY,. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat. Neoplasia 2010; 12: 697-707.
41. Jain RK, Baxter LT,. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48: 7022-32. (Pubitemid 19013976)
42. Corot C, Port M, Guilbert I, Robert P, Raynal I, Robic C, Raynaud J, Prigent P, Dencausse A, Idee J,. Superparamagnetic contrast agents. In:, Mondo MMJ, Bulte JWM, eds. Molecular and cellular MR contrast agents. Boca Raton: CRC Press, 2007. 59-83.